I always found that study to be interesting, since I’d like to think Verapamil is a worthwhile topical compound. The results are unfortunate, but I find this excerpt from the aforementioned 2011 patent add-on to be interesting:
”The inventor treated several patients’ Peyronies’s Disease and penis enlargement patients with the recommended dosing and frequency for direct Verapamil injections into the penis and into plaque with no observable effect. However, the inventor discovered that certain doses of Calcium Channel Blockers and Calmodulin Blockers, when applied topically, infused continuously, or applied intermittently at a higher frequency than was recommended in the medical literature improved their clinical efficacy.”
So what he essentially alleges, is that you have to use much more than the typical dose, with more frequent application for it to work as it should on the tunica. Not sure where I stand on the whole thing. I’m glad that apparently he found a way to properly utilize such a compound, but the results of both studies leave me feeling somewhat conflicted.
I assume that in the study mentioned in the earlier post they used the ‘typical’ dose. They said that even though it didn’t infiltrate the tunica there was a small systemic absorption. So it could be that the patent holder used much more than the typical dose and even though it didn’t infiltrate the tunica it was absorbed systemically and eventually it reached the tunica(?).
Starting stats: 6.4" / 5.6" Current Stats: 7.4" / 5.8" Short term goal: 7" / 6" Long term goal: 8" / 6.5"